Patents by Inventor Christopher John O'Donnell

Christopher John O'Donnell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20240051917
    Abstract: The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula I: as defined in the specification. The invention is also directed to compositions containing and uses of the compounds of formula I.
    Type: Application
    Filed: May 15, 2023
    Publication date: February 15, 2024
    Inventors: Anton Fran Joseph FLIRI, Randall J. GALLUSCHUN, Christopher John O'DONNELL, Jacob Bradley SCHWARZ, Barbara Eileen SEGELSTEIN
  • Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
    Patent number: 11712480
    Abstract: The present invention is directed to novel heteroaryl sulfone-based conjugation handles of the formula: (wherein R1, R2, Het, D, E, X, Y, Z, m, n, p, q, r, s and t are as defined herein), methods for their preparation, their use in synthesizing antibody drug conjugates, and the resulting antibody drug conjugates made with components having heteroaryl sulfone-based conjugation handles.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: August 1, 2023
    Assignee: Pfizer Inc.
    Inventors: Russell George Dushin, Daniel P. Uccello, Jeremy Starr, Ye Che, Mark Flanagan, Jeffrey M. Casavant, Christopher John O'Donnell, Gary Frederick Filzen, Jennifer Young, Joseph A. Abramite, Lawrence N. Tumey, Ludivine Moine, Adam Matthew Gilbert, Lee R. Roberts
  • HETEROARYL SULFONE-BASED CONJUGATION HANDLES, METHODS FOR THEIR PREPARATION, AND THEIR USE IN SYNTHESIZING ANTIBODY DRUG CONJUGATES
    Publication number: 20210308276
    Abstract: The present invention is directed to novel heteroaryl sulfone-based conjugation handles of the formula: (wherein R1, R2, Het, D, E, X, Y, Z, m, n, p, q, r, s and t are as defined herein), methods for their preparation, their use in synthesizing antibody drig conjugates, and the resulting antibody drig conjugates made with components having heteroaryl sulfone-based conjugation handles.
    Type: Application
    Filed: July 31, 2017
    Publication date: October 7, 2021
    Applicant: PFIZER INC.
    Inventors: Russell George DUSHIN, Daniel P. UCCELLO, Jeremy STARR, Ye CHE, Mark FLANAGAN, Jeffrey M. CASAVANT, Christopher John O'DONNELL, Gary Frederick FILZEN, Jennifer YOUNG, Joseph A. ABRAMITE, Lawrence N. TUMEY, Ludivine MOINE, Adam Matthew GILBERT, Lee R. ROBERTS
  • Bifunctional cytotoxic agents
    Patent number: 10391182
    Abstract: Cytotoxic dimers comprising CBI-based and/or CPI-based sub-units, antibody drug conjugates comprising such dimers, and to methods for using the same to treat cancer and other conditions.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: August 27, 2019
    Assignee: Pfizer Inc.
    Inventors: Andreas Maderna, Matthew David Doroski, Zecheng Chen, Hud Lawrence Risley, Jeffrey Michael Casavant, Christopher John O'Donnell, Alexander M. Porte, Chakrapani Subramanyam
  • HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20190100491
    Abstract: The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula I: as defined in the specification. The invention is also directed to compositions containing and uses of the compounds of formula I.
    Type: Application
    Filed: September 6, 2018
    Publication date: April 4, 2019
    Inventors: Anton Franz Joseph, Fliri, Randall J. Gallaschun, Christopher John O'Donnell, Jacob Bradley Schwarz, Barbara Eileen Segelsein
  • BIFUNCTIONAL CYTOTOXIC AGENTS
    Publication number: 20180339060
    Abstract: Cytotoxic dimers comprising CBI-based and/or CPI-based sub-units, antibody drug conjugates comprising such dimers, and to methods for using the same to treat cancer and other conditions.
    Type: Application
    Filed: August 2, 2018
    Publication date: November 29, 2018
    Applicant: PFIZER INC.
    Inventors: Andreas MADERNA, Matthew David DOROSKI, Zecheng CHEN, Hud Lawrence RISLEY, Jeffrey Michael CASAVANT, Christopher John O'DONNELL, Alexander M. PORTE, Chakrapani SUBRAMANYAM
  • Bifunctional cytotoxic agents
    Patent number: 10086085
    Abstract: Cytotoxic dimers comprising CBI-based and/or CPI-based sub-units, antibody drug conjugates comprising such dimers, and to methods for using the same to treat cancer and other conditions.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: October 2, 2018
    Assignee: Pfizer Inc.
    Inventors: Andreas Maderna, Matthew David Doroski, Zecheng Chen, Hud Lawrence Risley, Jeffrey Michael Casavant, Christopher John O'Donnell, Alexander M. Porte, Chakrapani Subramanyam
  • Spliceostatin analogs and methods for their preparation
    Patent number: 9764040
    Abstract: The present invention is directed to novel cytotoxic spliceostatin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: September 19, 2017
    Assignee: Pfizer Inc.
    Inventors: Chakrapani Subramanyam, Frank Erich Koehn, Kenneth John Dirico, Alessandra S. Eustaquio, Michael Eric Green, Haiyin He, Min He, Christopher John O'Donnell, Sujiet Puthenveetil, Anokha Ratnayake, Jesse Alexander Teske, Hui Yu Yang
  • Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders
    Patent number: 9751877
    Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: September 5, 2017
    Assignee: PFIZER INC.
    Inventors: Martin Youngjin Pettersson, Douglas Scott Johnson, Chakrapani Subramanyam, Christopher John O'Donnell, Christopher William am Ende, Michael Eric Green, Nandini Chaturbhai Patel, Cory Michael Stiff, Tuan Phong Tran, Gregory Wayne Kauffman, Antonia Friederike Stepan, Patrick Robert Verhoest
  • HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20170247360
    Abstract: The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula I: as defined in the specification. The invention is also directed to compositions containing and uses of the compounds of formula I.
    Type: Application
    Filed: May 12, 2017
    Publication date: August 31, 2017
    Inventors: ANTON FRANZ JOSEPH FLIRI, RANDALL JAMES GALLASCHUN, CHRISTOPHER JOHN O'DONNELL, JACOB BRADLEY SCHWARZ, BARBARA EILEEN SEGELSTEIN
  • SPLICEOSTATIN ANALOGS AND METHOS FOR THEIR PREPARATION
    Publication number: 20170014523
    Abstract: The present invention is directed to novel cytotoxic spliceostatin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.
    Type: Application
    Filed: September 29, 2016
    Publication date: January 19, 2017
    Inventors: Chakrapani SUBRAMANYAM, Frank Erich KOEHN, Kenneth John DIRICO, Alessandra S. EUSTAQUIO, Michael Eric GREEN, Haiyin HE, Min HE, Christopher John O'DONNELL, Sujiet PUTHENVEETIL, Anokha RATNAYAKE, Jesse Alexander TESKE, Hui Yu YANG
  • Spliceostatin analogs and methods for their preparation
    Patent number: 9504669
    Abstract: The present invention is directed to novel cytotoxic spliceostatin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: November 29, 2016
    Assignee: Pfizer Inc.
    Inventors: Chakrapani Subramanyam, Frank Erich Koehn, Kenneth John Dirico, Alessandra S. Eustaquio, Michael Eric Green, Haiyin He, Min He, Christopher John O'Donnell, Sujiet Puthenveetil, Anokha Ratnayake, Jesse Alexander Teske, Hui Yu Yang
  • HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20160272625
    Abstract: The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula I: as defined in the specification. The invention is also directed to compositions containing and uses of the compounds of formula I.
    Type: Application
    Filed: June 1, 2016
    Publication date: September 22, 2016
    Applicant: PFIZER INC.
    Inventors: ANTON FRANZ JOSEPH FLIRI, RANDALL JAMES GALLASCHUN, CHRISTOPHER JOHN O'DONNELL, JACOB BRADLEY SCHWARZ, BARBARA EILEEN SEGELSTEIN
  • Cytotoxic peptides and antibody drug conjugates thereof
    Patent number: 9249186
    Abstract: The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: February 2, 2016
    Assignee: Pfizer Inc.
    Inventors: Matthew David Doroski, Andreas Maderna, Christopher John O'Donnell, Chakrapani Subramanyam, Beth Vetelino, Russell George Dushin, Pavel Strop, Edmund Idris Graziani
  • Novel Pyrido[1,2-a]Pryazines And Their Use in the Treatment of Neurodegenerative and Neurological Disorders
    Publication number: 20160024088
    Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Application
    Filed: October 7, 2015
    Publication date: January 28, 2016
    Inventors: Martin Youngjin Pettersson, Douglas Scott Johnson, Chakrapani Subramanyam, Christopher John O'Donnell, Christopher William am Ende, Michael Eric Green, Nandini Chaturbhai Patel, Cory Michael Stiff, Tuan Phong Tran, Gregory Wayne Kauffman, Antonia Friederike Stepan, Patrick Robert Verhoest
  • SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION
    Publication number: 20160022626
    Abstract: The present invention is directed to novel cytotoxic spliceostatin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.
    Type: Application
    Filed: August 5, 2015
    Publication date: January 28, 2016
    Inventors: Chakrapani SUBRAMANYAM, Frank Erich Koehn, Kenneth John Dirico, Alessandra S. Eustaquio, Michael Eric Green, Haiyin He, Min He, Christopher John O'Donnell, Sujiet Puthenveetil, Anokha Ratnayake, Jesse Alexander Teske, Hui Yu Yang
  • Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders
    Patent number: 9193726
    Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: November 24, 2015
    Assignee: Pfizer Inc.
    Inventors: Martin Youngjin Pettersson, Douglas Scott Johnson, Chakrapani Subramanyam, Christopher John O'Donnell, Christopher William am Ende, Michael Eric Green, Nandini Chaturbhai Patel, Cory Michael Stiff, Tuan Phong Tran, Gregory Wayne Kauffman, Antonia Friederike Stepan, Patrick Robert Verhoest
  • CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF
    Publication number: 20150307551
    Abstract: The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.
    Type: Application
    Filed: July 8, 2015
    Publication date: October 29, 2015
    Inventors: Matthew David DOROSKI, Andreas MADERNA, Christopher John O'DONNELL, Chakrapani SUBRAMANYAM, Beth VETELINO, Russell George DUSHIN, Pavel STROP, Edmund Idris GRAZIANI
  • Spliceostatin analogs and methods for their preparation
    Patent number: 9169264
    Abstract: The present invention is directed to novel cytotoxic spliceostatin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: October 27, 2015
    Assignee: Pfizer Inc.
    Inventors: Chakrapani Subramanyam, Frank Erich Koehn, Kenneth John Dirico, Alessandra S. Eustaquio, Michael Eric Green, Haiyin He, Min He, Christopher John O'Donnell, Sujiet Puthenveetil, Anokha Ratnayake, Jesse Alexander Teske, Hui Yu Yang
  • Cytotoxic peptides and antibody drug conjugates thereof
    Patent number: 9138486
    Abstract: The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: September 22, 2015
    Assignee: Pfizer Inc.
    Inventors: Matthew David Doroski, Andreas Maderna, Christopher John O'Donnell, Chakrapani Subramanyam, Beth Vetelino, Russell George Dushin, Pavel Strop, Edmund Idris Graziani